Amoxicillin and clarithromycin and omeprazole combination regimen - DAVA Pharmaceuticals

Drug Profile

Amoxicillin and clarithromycin and omeprazole combination regimen - DAVA Pharmaceuticals

Alternative Names: Omeclamox-Pak

Latest Information Update: 25 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DAVA Pharmaceuticals
  • Developer Pernix Therapeutics Holdings
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antibacterials; Antiulcers; Gastric antisecretories; Macrolides; Penicillins; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 50S ribosomal subunit inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Helicobacter infections

Most Recent Events

  • 16 Dec 2014 GastroEntero Logic LLC files sNDA for revisions to the labelling of Omeclamox®-Pak in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top